What is Exploratory IND studies?
IND stands for Investigational New Drugs. Exploratory IND studies usually involve very limited human exposure and have no therapeutic or diagnostic intent.... Read More
MSD divests six brands to Zydus Cadila in India
Posted on30 Dec 2016
TagsAxeten, brand acquisition, Deca-Durabolin, Durabolin, MSD, Multiload, Sicastat, Sustanon, Zydus cadila
Comments0
Ahmedabad-based drug maker Zydus Cadila has acquired six brands from the Indian unit of US pharmaceutical giant Merck for an undisclosed amount.... Read More
USFDA approved first drug for spinal muscular atrophy
Posted on29 Dec 2016
TagsBiogen, Fast Track designation, Ionis Pharmaceuticals, Nusinersen, priority review, spinal muscular atrophy, Spinraza
Comments0
The U.S. Food and Drug Administration today approved Spinraza (nusinersen), the first drug approved to treat children and adults with spinal muscular... Read More
Novartis to acquire Ziarco Group Limited to strengthen the dermatology portfolio
Novartis announced today that it has entered into a definitive agreement for the acquisition of Ziarco Group Limited, a privately held company... Read More
BMS exclusive worldwide license agreement with PsiOxus Therapeutics for NG-348
BMS and PsiOxus Therapeutics, Ltd. announced an agreement granting Bristol-Myers Squibb exclusive worldwide rights to NG-348, a pre-clinical stage, “armed” oncolytic virus... Read More
ARMO BioSciences’ Immunotherapy AM0010 Receives Orphan Designation in Europe
Posted on24 Dec 2016
TagsEuropean Medicine Agency, Orphan Designation in Europe, orphan drug, orphan drug act, orphan drug designation
Comments0
ARMO BioSciences, Inc., a clinical-stage immuno-oncology company, announced that the European Commission (EC) has granted the Company’s lead investigational immuno-oncology drug AM0010... Read More
Celgene’s Otezla (Apremilast) receives Japanese regulatory approval
Posted on24 Dec 2016
TagsApremilast, Celgene, drug regulatory body in japan, Labor and Welfare, Ministry of Health, Plaque psoriasis, psoriasis
Comments0
Brand Name: Otezla Molecule: Apremilast Developed By: Celgene Corporation Apremilast (brand name Otezla) is a medication for the treatment of certain types... Read More
Sun Pharma to acquire Novartis’s branded drug Odomzo
Posted on23 Dec 2016
Comments0
Sun Pharmaceutical Industries Ltd will acquire the NOVARTIS’s branded cancer drug Odomzo for an upfront payment of $175 million. Odomzo is a... Read More
USFDA approved new drug Rubraca, rucaparib
The U.S. Food and Drug Administration today granted accelerated approval to Rubraca (rucaparib) to treat women with a certain type of ovarian... Read More
Novartis, Conatus Pharma to co-develop liver disease drug, emricasan
Novartis announced the signing of an exclusive option, collaboration and license agreement with Conatus Pharmaceuticals Inc., a biotechnology company focused on the... Read More